Event, FDA Approval, Positive Results, Partnership, and Marketing Authorization - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Lilly, and GSK

NEW YORK, September 9, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline plc (NYSE: GSK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On September 3, 2013, Pfizer Inc. (Pfizer) announced its participation in the upcoming Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2013. According to the Company, Frank D'Amelio, Executive Vice President of Business Operations and CFO, will hold a discussion during the event, and Pfizer invites investors and general public to listen to its webcast scheduled to begin at 4:05 p.m. EDT. Pfizer further informed that the webcast can be accessed by clicking on the "Morgan Stanley Global Healthcare Conference" link in its Investor Relations website. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-04/PFE]

--

Merck & Co. Inc. Research Report

On September 4, 2013, Merck & Co. Inc. (Merck) announced that it has received the US FDA approval to manufacture bulk varicella at the Company's site in Durham, North Carolina. Pfizer reported that the FDA approval will enable the site to produce bulk varicella supply for the US, for use in Merck's vaccines to protect against chickenpox and shingles, and help boost Merck's overall global supply capabilities. Julie Gerberding, M.D., President of Merck Vaccines, stated, "This is an important step forward in our long-term strategy to reach more and more people around the world with Merck's vaccines." The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-04/MRK]

--

Bristol-Myers Squibb Company Research Report

On September 2, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb) and AstraZeneca announced the SAVOR clinical trial results, which was conducted over 16,492 adult patients with type 2 diabetes at high risk for cardiovascular events. The Companies reported that the primary safety objective was met by Onglyza (saxagliptin), demonstrating  no increased risk for the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction (MI) or non-fatal ischemic stroke, when added to a patient's current standard of care (with or without other anti-diabetic therapies), as compared to placebo. Furthermore, the Company informed that Onglyza did not meet the primary efficacy endpoint of superiority to placebo for the same composite endpoint. Brian Daniels, MD, Senior Vice President of Global Development and Medical Affairs, Research and Development at Bristol-Myers Squibb, commented, "No other DPP-4 inhibitor and few other anti-hyperglycemic agents have been studied as extensively as Onglyza to address the question of cardiovascular safety." Daniels added, "Bristol-Myers Squibb and AstraZeneca are dedicated to meeting needs of physicians and patients in diabetes care and helping to ensure a better understanding of the value of our medications." The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-04/BMY]

--

Eli Lilly and Company Research Report

On August 29, 2013, Eli Lilly and Company (Lilly) announced its joint research collaboration with Humana Inc. (Humana). According to Lilly, its partnership with Humana reflects a shared commitment by both the Companies to address the challenges of improving quality of care and reducing treatment costs in today's complex and changing health care environment. William Fleming, Pharm.D., President of Humana Pharmacy Solutions, said, "Pairing Humana's clinical expertise and rich, de-identified patient data with Lilly's history and experience across many disease states allows us to maximize the potential benefits for patient care and savings." Fleming continued, "By leveraging our collective capabilities, we can work to address the critical health care needs facing our country." The Full Research Report on Eli Lilly and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-04/LLY]

--

GlaxoSmithKline plc Research Report

On September 2, 2013, GlaxoSmithKline plc (GSK) announced that its Tafinlar (dabrafenib) has been granted a marketing authorization by the European Commission. GSK reported that Tafinlar is an oral targeted treatment indicated in monotherapy for unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) in adult patients with a BRAF V600 mutation. Paolo Paoletti, M.D., President of GlaxoSmithKline Oncology, stated, "Today's authorisation of Tafinlar represents an important step in GSK's ongoing effort to bring new treatment options to cancer patients, especially as we have brought it to market in less than five years after our initial testing." Paoletti continued, "With this new personalised medicine, we hope to make a meaningful difference in the lives of appropriate patients with metastatic melanoma; a devastating disease and a cancer with one of the lowest survival rates." The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-04/GSK]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by an analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports